Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.54 |
| ▸ | ELANE | P08246 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14446354 | 0.91 | ATM (0.59) | GABRA1GABRB1ELANEALDH1A1KMT2A | |
| SCHEMBL18978115 | 0.87 | KMT2A (0.69) | GABRA1GABRB1ELANEALDH1A1KMT2A | |
| SCHEMBL1534312 | 0.87 | KMT2A (0.69) | GABRA1GABRB1ELANEALDH1A1KMT2A | |
| SCHEMBL20496485 | 0.87 | KMT2A (0.63) | ELANEALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL6322882 | 0.85 | KMT2A (0.61) | ALDH1A1KMT2ASMN1; SMN2LMNAMEN1 | |
| SCHEMBL19018120 | 0.82 | KMT2A (0.62) | ELANEALDH1A1KMT2A | |
| SCHEMBL18978109 | 0.82 | KMT2A (0.62) | ELANEALDH1A1KMT2A | |
| SCHEMBL2464374 | 0.81 | HTT (0.59) | ELANEALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL151012 | 0.80 | KMT2A (0.64) | ALDH1A1KMT2AMEN1GAAHTT | |
| SCHEMBL15281240 | 0.80 | KMT2A (0.59) | ELANEALDH1A1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022232-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | SCHRODI YANN (US) | 2017-01-26 | — | — | US | disclosed |
| US-9273081-B2 | Method for in-situ formation of metathesis catalysts | ExxonMobil Product Solutions Company | 2016-03-01 | — | — | US | disclosed |
| US-20150299235-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | ExxonMobil Product Solutions Company | 2015-10-22 | — | — | US | disclosed |
| US-20130204026-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | MATERIA, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2011119778-A2 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | SCHRODI YANN (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299235-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | CHRM1, ACSL1, LOXL1 | GABRA1 4591/4885GABRB1 4687/4885ELANE 822/4885 |
| US-20170022232-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | CHRM1, ACSL1, LOXL1 | GABRA1 4591/4885GABRB1 4687/4885ELANE 822/4885 |
| US-20130204026-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | CHRM1, ACSL1, LOXL1 | GABRA1 4591/4885GABRB1 4687/4885ELANE 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.